Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How do you know you've done any better?

M A Schneiderman

    Cancer
    |January 1, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Concurrent controlled randomized trials, particularly Phase II, accelerate cancer treatment advancements. Continuing comparative trials without statistical tests are recommended over unworkable historical-control methods for optimal patient care.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    David Byar as a supervisee.

    Controlled clinical trials·1995
    Same author

    Re: "Risk attribution and tobacco-related deaths".

    American journal of epidemiology·1995
    Same author

    More on torturing data.

    The New England journal of medicine·1994
    Same author

    Re: Attitudes and opinions regarding asbestos and cancer, 1934-1965.

    American journal of industrial medicine·1993
    Same author

    Asbestos-related cancer.

    Journal of the National Cancer Institute·1992
    Same author

    Fraudulent statistical methods.

    Biometrics·1991
    Same journal

    Toward exercise as standard care for older cancer survivors.

    Cancer·2026
    Same journal

    Maintenance therapy in gynecologic malignancies: Current and future state.

    Cancer·2026
    Same journal

    Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

    Cancer·2026
    Same journal

    Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

    Cancer·2026
    Same journal

    EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

    Cancer·2026
    Same journal

    Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

    Cancer·2026
    See all related articles

    Area of Science:

    • Oncology
    • Clinical Trials
    • Biostatistics

    Background:

    • Evaluating new cancer treatments is crucial for patient outcomes.
    • Traditional methods for assessing treatment efficacy can be slow and misleading.
    • The need for efficient and reliable clinical trial designs is paramount.

    Purpose of the Study:

    • To advocate for the use of concurrent controlled randomized trials in cancer research.
    • To propose and recommend Theodore Colton's scheme of continuing comparative trials.
    • To critically evaluate the historical-controls approach and the concept of "the epidemiology of treatment."

    Main Methods:

    • Analysis of concurrent controlled randomized trials, with emphasis on Phase II trials.
    • Examination of Theodore Colton's proposed continuing comparative trials.

    Related Experiment Videos

  • Critique of the historical-controls approach used by Gehan and Freireich.

    • Main Results:

    • Concurrent controlled randomized trials significantly expedite the introduction of effective cancer therapies.
    • Theodore Colton's continuing comparative trials are strongly recommended for their efficiency.
    • The historical-controls approach is deemed unworkable and largely rejected.
    • Early, uncontrolled study results can be deceptive when evaluating cancer treatments.

    Conclusions:

    • Concurrent controlled randomized trials are the most effective method for advancing cancer treatment development.
    • Continuing comparative trials offer a viable alternative to traditional statistical testing.
    • Identifying patient characteristics for personalized treatment ("epidemiology of treatment") is essential for optimal patient management.